# HER2 PARADIGM (NCT06750484)

> Trial of Trastuzumab Deruxtecan in Previously Treated HER2

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06750484
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Yale University
- Conditions: Breast Cancer Metastatic
- Interventions: Trastuzumab Deruxtecan
- Enrollment: 40
- Primary outcome: Objective Response Rate

## Indexed commentary on HER2 PARADIGM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=her2-paradigm-nct06750484